Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/NON-RI) disclosure by Cavendish Securities plc. The disclosure states that Cavendish Securities plc is an exempt principal trader and is connected to Allergy Therapeutics plc. The disclosure also includes information about the positions and short positions held by Cavendish Securities plc in Allergy Therapeutics plc's relevant securities. The disclosure states that Cavendish Securities plc owns and/or controls 190,573 relevant securities of Allergy Therapeutics plc, which represents 0.03% of the total. The disclosure also includes information about recent dealings by Cavendish Securities plc, including sales of 3,148 securities at a price of 2.6 per unit. The disclosure does not include any information about indemnity or option arrangements, agreements or understandings relating to options or derivatives, or any attachments such as a Supplemental Form 8 (Open Positions). The disclosure was made on September 27, 2023, and the contact person for the disclosure is Angela Teodorescu.